Glioblastoma Multiforme is the most common malignant tumor of the central nervous system, known for its resistance to conventional treatments. Despite advanced diagnostics and combined therapies, patient prognosis remains poor.
To tackle this challenge, an international consortium of seven partners has launched the NuCapCure project, integrating expertise from physics, chemistry, and biology to develop novel therapeutic methods. The goal is to induce tumor cells to biosynthesize compounds that enable their selective destruction combined with subsequent proton or neutron radiotherapy.
As part of the project, we provide irradiation experiments at the LVR-15 research reactor. To support treatment testing, we are preparing the newly reconstructed horizontal irradiation channel HK-5, which will provide optimal parameters for neutron therapy.
Our expertise dates back to 2000–2002 when we participated in the first clinical studies of boron neutron capture therapy. These experiences now contribute to advancing treatment for still incurable tumors.
For more information about the NuCapCure project, visit nucapcure.eu.
